Results from randomized trial of pirfenidone in patients with chronic rejection (STOP-CLAD study).
Michael P CombsElizabeth A BelloliNicolas GargurevichKevin R FlahertySusan MurrayCraig J GalbánVibha N LamaPublished in: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation (2024)
Pirfenidone had no apparent impact on radiographic evidence of allograft dysfunction or pulmonary function decline in a single-center randomized trial of CLAD patients that did not meet enrollment goals but had an acceptable tolerance and side-effect profile.